David Branigan, Intellectual Property Watch; New Research Study Describes DNDi As A “Commons” For Public Health
"Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to
meet the public health needs of neglected populations by filling gaps
in drug development left by the for-profit pharmaceutical industry. A
new research study by the French Development Agency analysed DNDi’s
unique product development partnership (PDP) model, and found that it
“illustrate[s] what can be presented as a ‘commons’ within the area of
public health."
The research study, “DNDi, a Distinctive Illustration of Commons in the Area of Public Health,”
was published earlier this month by the Agence Française de
Développement (AFD), the French public development bank that “works in
many sectors — energy, healthcare, biodiversity, water, digital
technology, professional training, among others — to assist with
transitions towards a safer, more equitable, and more sustainable world:
a world in common,” according to its website."
Issues and developments related to ethics, information, and technologies, examined in the ethics and intellectual property graduate courses I teach at the University of Pittsburgh School of Computing and Information. My Bloomsbury book "Ethics, Information, and Technology" will be published in Summer 2025. Kip Currier, PhD, JD
Showing posts with label drug development. Show all posts
Showing posts with label drug development. Show all posts
Tuesday, February 26, 2019
New Research Study Describes DNDi As A “Commons” For Public Health; Intellectual Property Watch, February 25, 2019
Subscribe to:
Posts (Atom)